Immunotherapy in GU Cancers

>

The OncLive Immunotherapy in GU Cancers condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in genitourinary malignancies, specifically prostate cancer, urothelial carcinoma, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

Latest News

Viktor Grünwald, MD
Lenvatinib/Pembrolizumab Maintained Beneficial Outcomes When Evaluated by Tumor Size in RCC

February 2nd 2024

Lenvatinib/pembrolizumab demonstrated efficacy irrespective of tumor burden in advanced renal cell carcinoma in the overall patient population of the phase 3 CLEAR study.

Chung-Han Lee, MD, PhD
TKI and Immunotherapy Combo Efforts in RCC Remain of Interest as Treatment Arsenal Evolves

December 4th 2023

Marjorie Green, MD, senior vice president and head of late-stage oncology, global clinical development, Merck Research Laboratories
Adjuvant Pembrolizumab Improves OS in Select Patients With RCC After Nephrectomy

November 1st 2023

Tian Zhang, MD, MHS
Updated Data Continue to Aid IO-Based Frontline Treatment Decisions in Advanced RCC

October 24th 2023

RCC © stock.adobe.com
Retrospective Data Show Nephrectomy With Immune-Targeted Therapy Offers Potential PFS Benefit in Metastatic RCC

October 24th 2023

Video Series
Video Interviews

More News